

**LISTING OF CLAIMS**

This listing of claims replaces all other listings of claims.

1. (ORIGINAL) A method to treat an ocular condition in a patient comprising intraocularly implanting a composition comprising a sustained release matrix and a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof in an amount effective to treat the condition.
2. (ORIGINAL) The method of claim 1 to treat a condition selected from the group consisting of a condition associated with an immunologic reaction, an ocular age related condition, a ocular degenerative condition, a condition associated with ocular moisture, a post-corneal surgery condition, and combinations thereof.
3. (ORIGINAL) The method of claim 1 to treat a condition selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, pemphigus, Sjögren's syndrome, Behcet's syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.
4. (ORIGINAL) The method of claim 1 wherein the composition is implanted on the sclera.

5. (ORIGINAL) The method of claim 1 wherein the matrix contains in the range of about 3 mg of the drug to about 5 mg of the drug.

6. (CURRENTLY AMENDED) A method to treat an ocular condition in a patient comprising intraocularly administering a composition comprising a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof, the drug at a concentration up to about 200  $\mu\text{g/ml}$  in a pharmaceutically acceptable formulation effective to treat the condition without substantial toxicity wherein the composition is administered by at least one of intraocular injection or intraocular implantation.

7. (ORIGINAL) The method of claim 6 to treat a condition selected from the group consisting of a condition associated with an immunologic reaction, an ocular age related condition, a ocular degenerative condition, a condition associated with ocular moisture, a post-corneal surgery condition, and combinations thereof.

8. (ORIGINAL) The method of claim 6 to treat a condition selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, pemphigus, Sjögren's syndrome, Behçet's syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous

choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.

9. (CANCEL)

10. (ORIGINAL) The method of claim 6 wherein the composition further comprises Cyclosporin A, tacrolimus, and combinations thereof.

11. (CURRENTLY AMENDED) A method to treat an ocular condition in a patient comprising intraocularly administering a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation effective to treat the condition by a method selected from the group consisting of topical administration at a concentration of about 50 pg/ml to ~~about 50 µg/ml less than 1 µg/ml~~, subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 µg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 µg/ml, or retrobulbar injection at a dose in the range of about 20 µg/ml to about 200 µg/ml.

12. (ORIGINAL) The method of claim 11 wherein injection is intravitreal at a dose of about 50 µg/0.1 ml.

13. (ORIGINAL) The method of claim 11 to treat a condition selected from the group consisting of a condition associated with an immunologic reaction, an

ocular age related condition, a ocular degenerative condition, a condition associated with ocular moisture, a post-corneal surgery condition, and combinations thereof.

14. (ORIGINAL) The method of claim 11 to treat a condition selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, pemphigus, Sjögren's syndrome, Behcet's syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.

15. (CURRENTLY AMENDED) An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200 µg/ml by at least one of intraocular injection or intraocular implantation, or the composition is administered topically at a concentration in the range between about 50 pg/ml to less than 1 µg/ml.

16. (CANCEL)

17. (ORIGINAL) The method of claim 15 wherein the composition is administered by subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 µg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 µg/ml, or retrobulbar injection at a dose in the range of about 20 µg/ml to about 200 µg/ml.

18-19. (CANCEL)

20. (CURRENTLY AMENDED) An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200 µg/ml by at least one of intraocular injection or intraocular implantation, or the composition is administered topically at a concentration in the range between about 50 µg/ml to less than 1 µg/ml.

21. (CANCEL)

22. (ORIGINAL) The method of claim 20 wherein the composition is administered by subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 µg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 µg/ml, or retrobulbar injection at a dose in the range

of about 20  $\mu\text{g}/\text{ml}$  to about 200  $\mu\text{g}/\text{ml}$ .

23-24. (CANCEL)

25. (CURRENTLY AMENDED) A method to treat an ocular condition in a patient comprising intraocularly administering to the patient a pharmaceutically acceptable formulation of a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof, in an amount up to about 200  $\mu\text{g}/\text{ml}$  effective to treat an ocular condition without substantial toxicity and at least one antibiotic, wherein the composition is administered by at least one of intraocular injection or intraocular implantation at a concentration up to about 200  $\mu\text{g}/\text{ml}$ , or the composition is administered topically at a concentration in the range between about 50  $\mu\text{g}/\text{ml}$  to less than 1  $\mu\text{g}/\text{ml}$ .

26. (CANCEL)

27. (CURRENTLY AMENDED) A therapeutic composition for treating an ocular condition consisting essentially of rapamycin in a physiologically acceptable intraocular formulation and at a dose up to about 200  $\mu\text{g}$  effective to treat the ocular condition without substantial toxicity wherein the composition is formulated for topical administration at a concentration in the range between about 50  $\mu\text{g}/\text{ml}$  to less than 1  $\mu\text{g}/\text{ml}$ , or the composition is formulated as an injectable at a concentration up to about 200  $\mu\text{g}/\text{ml}$ .

28-29. (CANCEL)

30. (CURRENTLY AMENDED) A therapeutic composition for treating an ocular condition consisting essentially of ascomycin in a physiologically acceptable intraocular formulation and at a dose up to about 200 µg effective to treat the ocular condition without substantial toxicity wherein the composition is formulated for topical administration at a concentration in the range between about 50 µg/ml to less than 1 µg/ml, or the composition is formulated as an injectable at a concentration up to about 200 µg/ml.

31-32. (CANCEL)

33. (ORIGINAL) A therapeutic composition for treating an ocular condition comprising a physiologically acceptable matrix and a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof in an amount ranging between 3 mg and 5 mg for intraocular implantation.

34. (ORIGINAL) The composition of claim 33 wherein the matrix comprises a substance selected from the group consisting of lipid, polyvinyl alcohol, polyvinyl acetate, polycaprolactone, poly(glycolic)acid, poly(lactic)acid, and combinations thereof.

35. (ORIGINAL) The composition of claim 33 wherein the matrix sustainedly releases the drug.

36. (ORIGINAL) The composition of claim 33 wherein the matrix releases the drug at a rate selected from the group consisting of less than about 50 µg/day, in a range between about 50 pg/day to about 50 µg/day, and in a range between about 1 µg/day to about 5 µg/day.

37. (CURRENTLY AMENDED) A method to treat an ocular condition in a patient comprising intraocularly administering a composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation effective to treat the condition by a method selected from the group consisting of topical administration at a concentration [[of]] between about 50 pg/ml to about 50 µg/ml less than 1 µg/ml, subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 µg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 µg/ml, or retrobulbar injection at a dose in the range of about 20 µg/ml to about 200 µg/ml.

38. (ORIGINAL) The method of claim 37 wherein injection is intravitreal at a dose of about 50 µg/0.1 ml.

39. (ORIGINAL) The method of claim 37 to treat a condition selected from the group consisting of a condition associated with an immunologic reaction, an

ocular age related condition, a ocular degenerative condition, a condition associated with ocular moisture, a post-corneal surgery condition, and combinations thereof.

40. (ORIGINAL) The method of claim 37 to treat a condition selected from the group consisting of dry eye disease, scleritis, neuritis, papillitis, uveitis, retinopathy, retinitis pigmentosa, macular degeneration, pemphigus, Sjögren's syndrome, Behçet's syndrome, toxoplasmosis, Birdshot choroidopathy, histoplasmosis, pars planitis, sarcoidosis, sympathetic ophthalmia, serpiginous choroidopathy, diffuse pigment epitheliopathy, Vogt-Koyanagi syndrome, polyarteritis nodosa, and juvenile rheumatic arthritis.